Arrowhead Pharmaceuticals, Inc.: share-based compensation expense
Arrowhead Pharmaceuticals share-based compensation expense: $63.4 million for the year ending 2025-09-30, down 14.3% on the year. 16 values since 2010.
All Arrowhead Pharmaceuticals, Inc. financial histories
At a glance
Arrowhead Pharmaceuticals reported share-based compensation expense of $63.4 million for the year ending 2025-09-30, down 14.3% from $74.0 million a year earlier. From 2010 to 2025 it grew at a compound 28.8% a year, from $1.42 million to $63.4 million. Across the last five reported years it ranged from $63.4 million (2025-09-30) to $120.9 million (2022-09-30). That was 7.6% of revenue ($829.4 million) for the same year.
Computed from the values in the table below, in USD; each links to the filing it came from.
What this measure means
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
Exact concept: us-gaap:ShareBasedCompensation. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2009-10-01 to 2025-09-30. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2024-10-01 | 2025-09-30 | 63,366,000 | USD | 2025-11-25 | 10-K · 0000879407-25-000029 SEC |
| 2023-10-01 | 2024-09-30 | 73,968,000 | USD | 2025-11-25 | 10-K · 0000879407-25-000029 SEC |
| 2022-10-01 | 2023-09-30 | 78,130,000 | USD | 2025-11-25 | 10-K · 0000879407-25-000029 SEC |
| 2021-10-01 | 2022-09-30 | 120,893,000 | USD | 2024-11-26 | 10-K · 0001628280-24-049277 SEC |
| 2020-10-01 | 2021-09-30 | 76,673,000 | USD | 2023-11-29 | 10-K · 0001628280-23-040219 SEC |
| 2019-10-01 | 2020-09-30 | 43,383,000 | USD | 2022-11-28 | 10-K · 0001628280-22-030869 SEC |
| 2018-10-01 | 2019-09-30 | 12,393,000 | USD | 2021-11-22 | 10-K · 0001564590-21-057888 SEC |
| 2017-10-01 | 2018-09-30 | 8,454,607 | USD | 2020-11-23 | 10-K · 0001564590-20-054893 SEC |
| 2016-10-01 | 2017-09-30 | 7,891,595 | USD | 2019-11-25 | 10-K · 0001564590-19-044376 SEC |
| 2015-10-01 | 2016-09-30 | 11,595,816 | USD | 2018-12-11 | 10-K · 0001564590-18-030805 SEC |
| 2014-10-01 | 2015-09-30 | 10,232,897 | USD | 2017-12-12 | 10-K · 0001564590-17-024834 SEC |
| 2013-10-01 | 2014-09-30 | 5,696,173 | USD | 2016-12-14 | 10-K · 0001564590-16-030217 SEC |
| 2012-10-01 | 2013-09-30 | 1,536,271 | USD | 2015-12-14 | 10-K · 0001564590-15-011489 SEC |
| 2011-10-01 | 2012-09-30 | 1,241,404 | USD | 2014-11-25 | 10-K · 0001564590-14-005961 SEC |
| 2010-10-01 | 2011-09-30 | 1,376,921 | USD | 2012-12-28 | 10-K · 0001193125-12-517638 SEC |
| 2009-10-01 | 2010-09-30 | 1,424,293 | USD | 2011-12-20 | 10-K · 0001193125-11-347334 SEC |
Related ARROWHEAD PHARMACEUTICALS, INC. histories
Inspect the source
- Entity
- ARROWHEAD PHARMACEUTICALS, INC. / CIK 0000879407
- Captured
- SEC response SHA-256
df8855dae0055b71bd49c85d7ebc47f72ea6d71536d6bfd857bed2fe95364863
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
The MCP server is free and MIT-licensed: npx -y canli-mcp. If these records help your research, a star on GitHub helps other researchers find them.
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000879407.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))